ISSN:
1432-2072
Keywords:
Fluphenazine Enanthate
;
Coma
;
Extrapyramidal
;
Creatine Phosphokinase
;
Hypothalmus
;
Neuroleptic “Malignant” Syndrome
;
Muscular Figidity
;
“Lethal Catatonia”
;
Hyperpyrexia
;
Malignant Hyperpyrexia
Source:
Springer Online Journal Archives 1860-2000
Topics:
Medicine
Notes:
Abstract Beginning one day after receiving fluphenazine enanthate (Prolixin Enanthate®), 25 mg, subcutaneously, an acute schizophrenic girl with mixed schizoaffective and excited catatonic symptomatology became mute and withdrawn, then developed severe muscular rigidity and hyperpyrexia, and finally became comatose. The patient developed large increases in serum creatine phosphokinase (CPK) activity by the third day of this syndrome. The previously described symptoms, which have been labeled the neuroloptic “malignant” syndrome (Delay and Deniker, 1968), diminished with supportive treatment and intravenous benztropine mesylate (Cogentin®). Because of renewed psychotic behavior, phenothiazine treatment was eventually restarted, including treatment with fluphenazine enanthate, without recurrence of the extrapyramidal or hypothalamic symptoms. The difficulty in distinguishing between the neuroleptic “malignant” syndrome and Stauder's “acute lethal catatonia” is emphasized. The relationship between these syndromes and malignant hyperpyrexia is discussed. Possible causes of the increased serum CPK activity are discussed.
Type of Medium:
Electronic Resource
URL:
http://dx.doi.org/10.1007/BF00429281
Permalink
